Highlights TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-03-06 am EST			5-day change	1st Jan Change
0.0706 ^EUR	-3.95%		+2.32%	+8.28%

Jan. 05	TME Pharma N.V. Provides Update on Its Activities	CI
Nov. 17	TME Pharma N.V. Announces Extension of Certain Bond Agreements	CI

Highlights

Jan. 05	TME Pharma N.V. Provides Update on Its Activities	CI
25-10-29	TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-18	TME Pharma N.V. Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy with Signature of Option Framework Agreement with Singapore Eye Research Institute	CI
25-06-18	TME Pharma, Seri Sign New Deal for Clinical Development of Ophthalmic Disease Molecule	MT
25-06-18	TME Pharma N.V. and Singapore Eye Research Institute Sign Option Framework Agreement	CI
25-06-18	Singapore Eye Research Institute Signs Ophthalmology Framework Agreement with German Firm	MT
25-05-05	A month of zero gains on the stock market in April?
25-04-28	The bulls are hanging on!
25-04-25	TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-13	TME Pharma N.V. Announces Filing of Patents for Use of CCL2 Inhibitor NOX-E36 in Ophthalmology and Presentation at ARVO 2025 of Preclinical Data Showing Benefit in Glaucoma Filtration Surgery	CI
25-01-29	TME Pharma N.V. Announces Collaboration with Aimed Analytics for AI-Driven Drug Discovery and Optimization	CI
24-12-23	TME Pharma Raises GBP3 Million Via Public Offer	MT
24-12-23	TME Pharma: successful capital increase
24-12-12	TME Pharma Plans Equity Raise to Extend Financial Visibility	MT
24-12-04	TME Pharma: financing secured, but risk persists
24-12-04	TME Pharma to Raise Nearly EUR3 Million to Fund Drug Asset Transactions	MT
24-11-25	TME Pharma: new data on NOX-A12
24-11-23	TME Pharma N.V. Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting	CI
24-10-18	TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-10-18	TME Pharma N.V. Provides Clinical Update	CI
24-06-19	TME Pharma: in the red, a broker cuts its target
24-06-19	TME Pharma: Invest Securities reduces its target
24-04-25	TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-23	TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	CI
24-04-02	TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	CI